BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients
Second Phase 2 trial initiated from BioNTech’s proprietary individualized mRNA-based cancer vaccine platform iNeST Randomized…